Identification and characterization of cytochrome P4502D656B (CYP2D656B), a novel allele associated with the poor metabolizer phenotype.

被引：0

作者：

Gaedigk, A. ^{[1
]}

Eklund, J. D. ^{[1
]}

Pearce, R. E. ^{[1
]}

Leeder, J. S. ^{[1
]}

Alander, S. W. ^{[1
]}

Bradford, L. D. ^{[1
]}

Kennedy, M. J. ^{[1
]}

机构：

[1] Univ Louisville, Childrens Mercy Hosp, Morehouse Sch Med, Kansas City, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：S85 / S85

页数：1

共 50 条

[31] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype [J].

Ganesh, Soraya, V ;

Beunk, Lianne ;

Nikolik, Bojan ;

van der Weide, Jan ;

Bet, Pierre M. .

THERAPEUTIC DRUG MONITORING, 2021, 43 (05) :672-680

[32] Correlation between cytochrome P-450CYP2D6 CYP2D6) genotype and phenotype [J].

Chen, SQ ;

Wedlund, PJ .

ACTA PHARMACOLOGICA SINICA, 1999, 20 (07) :585-588

[33] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test [J].

Laine, K ;

Tybring, G ;

Härtter, S ;

Andersson, K ;

Svensson, JO ;

Widén, J ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :327-335

[34] FREQUENCY OF A SPECIFIC CYTOCHROME P4502D6B (CYP2D6B) MUTANT ALLELE IN CLINICALLY DIFFERENTIATED GROUPS OF PATIENTS WITH PARKINSON DISEASE [J].

AKHMEDOVA, SN ;

PUSHNOVA, EA ;

YAKIMOVSKY, AF ;

AVTONOMOV, VV ;

SCHWARTZ, EI .

BIOCHEMICAL AND MOLECULAR MEDICINE, 1995, 54 (02) :88-90

[35] Heterozygosity for the most common poor metabolizer allele (CYP2D6*4) was not associated with increased susceptibility to ankylosing spondylitis (AS) [J].

Marzouk, K. ;

Pope, A. ;

Hamilton, S. ;

Rahman, P. ;

Peddle, L. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :405-405

[36] Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10 [J].

Dong, A. N. ;

Ong, C. E. ;

Pan, Y. ;

Palanisamy, U. D. ;

Ismail, R. .

PUBLIC HEALTH GENOMICS, 2015, 18 :49-49

[37] IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE WITH A SINGLE-BASE DELETION IN EXON-3 AND ITS ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE [J].

SAXENA, R ;

SHAW, GL ;

RELLING, MV ;

FRAME, JN ;

MOIR, DT ;

EVANS, WE ;

CAPORASO, N ;

WEIFFENBACH, B .

HUMAN MOLECULAR GENETICS, 1994, 3 (06) :923-926

[38] The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes - Independent commentary [J].

Brosen, K .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (07) :S749-S750

[39] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype [J].

Martinez de Duenas, Eduardo ;

Ochoa Aranda, Enrique ;

Blancas Lopez-Barajas, Isabel ;

Ferrer Magdalena, Teresa ;

Bandres Moya, Fernando ;

Chicharro Garcia, Luis Miguel ;

Gomez Capilla, Jose A. ;

Zafra Ceres, Mercedes ;

de Haro, Tomas ;

Romero Llorens, Regina ;

Ferrer Albiach, Carlos ;

Ferriols Lisart, Rafael ;

Chover Lara, Dolores ;

Lopez Rodriguez, Angela ;

Munarriz Ferrandis, Javier ;

Olmos Anton, Santiago .

BREAST, 2014, 23 (04) :400-406

[40] CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment [J].

Almoguera, Berta ;

Riveiro-Alvarez, Rosa ;

Lopez-Castroman, Jorge ;

Dorado, Pedro ;

Vaquero-Lorenzo, Concepcion ;

Fernandez-Piqueras, Jose ;

LLerena, Adrian ;

Abad-Santos, Francisco ;

Baca-Garcia, Enrique ;

Dal-Re, Rafael ;

Ayuso, Carmen .

PHARMACOGENETICS AND GENOMICS, 2013, 23 (11) :627-630

← 1 2 3 4 5 →

Identification and characterization of cytochrome P4502D6*56B (CYP2D6*56B), a novel allele associated with the poor metabolizer phenotype.

Identification and characterization of cytochrome P4502D656B (CYP2D656B), a novel allele associated with the poor metabolizer phenotype.